Bvf Partners LP Il Insider Profile

242 Followers
Bvf Partners LP Il, See Explanation of Responses at ChemoCentryx, holds 548.94K shares in Repare Therapeutics (Ticker: RPTX), holds 294.63K shares in Kymera Therapeutics (Ticker: KYMR), holds 623.71K shares in Olema Pharmaceuticals (Ticker: OLMA). Most recently, Bvf Partners LP Il Bought ― shares of Repare Therapeutics on Nov 17, 2023 for an estimated value of 6.24M.
tipranks
Bvf Partners LP Il

Bvf Partners LP Il
ChemoCentryx (CCXI)
See Explanation of Responses

Ranked #34 out of 105,977 Corporate Insiders

Profitable Transactions

61%
134 out of 218 Profitable Transactions

Average Return

+37.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$5B
37.11%
21.84%
19.72%
5.99%
15.34% Others
A breakdown of Bvf Partners LP Il's holdings

Insider Roles

Repligen
(RGEN)
Indirect Beneficial Owner, Ten Percent Owner
Neurocrine
(NBIX)
See Explanation of Responses
MoonLake Immunotherapeutics
(MLTX)
Director, Ten Percent Owner
Structure Therapeutics, Inc. Sponsored ADR
(GPCR)
Ten Percent Owner
+26 other positions
Roles that Bvf Partners LP Il holds in companies

Most Profitable Insider Trade

Stock:
Gyre Therapeutics
(GYRE)
Rating:Informative Buy
Date:Jul 13, 2009 - Jul 13, 2010
Return:+622.60%
The most profitable trade made by Bvf Partners LP Il

Bvf Partners LP Il's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
CCXI
ChemoCentryx
Nov 05, 2015
Uninformative Sell
$177.51M
CTIC
CTI BioPharma
Jun 28, 2023
Uninformative Sell
80.59M
$0.00
Xenon
Mar 29, 2018
Ten Percent Owner
Uninformative Sell
$2.10M
Infinity Pharmaceuticals
Feb 16, 2021
See Explanation of Responses
Informative Sell
12.11M
$132.21K
Xoma
Jan 09, 2023
Director, See Remarks, Ten Percent Owner
Informative Buy
420.63K
$57.68M
GlycoMimetics
Nov 06, 2020
Ten Percent Owner
Informative Buy
3.29M
$964.59K
CNCE
Concert Pharma
Jun 12, 2019
Informative Sell
4.13M
$1.42M
Syndax Pharmaceuticals
Jun 20, 2018
Ten Percent Owner
Uninformative Sell
$1.33M
IMDZ
Immune Design
Dec 04, 2018
Informative Sell
1.65M
$2.17M
Pieris Pharmaceuticals
Sep 10, 2019
Ten Percent Owner
Informative Sell
224.50K
$63.77K
FPRX
Five Prime Therapeutics
Nov 13, 2020
Informative Sell
149.20M
$3.09M
Calithera Bio
May 26, 2020
Ten Percent Owner
Informative Sell
13.70M
$15.37K
Cytokinetics
Feb 18, 2020
See Explanaton of Responses
Informative Sell
16.92M
$220.60M
Merus
Oct 08, 2021
Ten Percent Owner
Informative Sell
31.22M
$5.59M
IDEAYA Biosciences
Feb 04, 2021
See Explanation of Responses
Informative Sell
835.36K
$7.20M
PRNB
Principia Biopharma
Kymera Therapeutics
Nov 06, 2023
Director, See Remarks and Footnotes
Informative Buy
5.30M
$5.93M
Olema Pharmaceuticals
Sep 14, 2023
Director, Ten Percent Owner
Uninformative Buy
$8.45M
Eledon Pharmaceuticals
May 09, 2023
Ten Percent Owner
Uninformative Buy
$174.03K
CytomX Therapeutics
See Explanation of Responses
$7.38M
Rain Therapeutics
Nov 10, 2022
Director, See Explanation of Responses, Ten Percent Owner
Informative Buy
9.97M
$3.88M
Repare Therapeutics
Nov 17, 2023
Ten Percent Owner
Informative Buy
6.24M
$2.73M
Cullinan Management
Jan 19, 2023
Ten Percent Owner
Uninformative Sell
$552.43K
Third Harmonic Bio, Inc.
Dec 22, 2022
Ten Percent Owner
Informative Buy
877.66K
$1.87M
Structure Therapeutics, Inc. Sponsored ADR
May 12, 2023
Ten Percent Owner
Uninformative Sell
$279.86M
MoonLake Immunotherapeutics
Director, Ten Percent Owner
$922.11M
Gyre Therapeutics
Nov 19, 2012
See Explanation of Responses
Informative Buy
5.24M
$58.23M
CASC
Cascadian Therapeutics
Dec 22, 2015
Informative Buy
$207.39M
Dynavax
Sep 11, 2009
Ten Percent Owner
Informative Sell
3.35M
$227.29M
Neurocrine
Oct 14, 2011
See Explanation of Responses
Informative Buy
175.53K
$1.02B
Repligen
Jul 08, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
5.50K
$1.74B
Epirus Biopharma
Dec 24, 2009
Ten Percent Owner
Informative Sell
2.54M
$13.66M
~ARRY
Array Biopharma
Jul 10, 2014
Uninformative Sell
2.25M
$596.76M
AMAG
Amag Pharmaceuticals
$14.15M
ARQL
Arqule
Jun 01, 2018
Informative Sell
5.18M
$15.43M
Rigel
Nov 20, 2013
Ten Percent Owner
Informative Sell
1.28M
$7.76M
TBRA
Tobira Therapeutics
Mar 25, 2014
Uninformative Sell
$47.19M
Curis
Apr 29, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
3.42M
$71.24M
~RPRX
Repros
$1.12M
Ligand Pharma
Mar 26, 2014
See Explanation of Responses
Informative Sell
5.48M
$7.55M
Palatin Technologies
Mar 03, 2014
Ten Percent Owner
Informative Sell
320.27K
$4.76M
ASTX
Astex Pharmaceuticals
Medicinova
Ten Percent Owner
$0.00
NPSP
NPS Pharma
List of latest transactions for each holding click on a transaction to see Bvf Partners LP Il's performance on stock

Bvf Partners LP Il insider profile FAQ

What is the percentage of profitable transactions made by Bvf Partners LP Il?
The percentage of profitable transactions made by Bvf Partners LP Il is 61%.
    What is the average return per transaction made by Bvf Partners LP Il?
    The average return per transaction made by Bvf Partners LP Il is 37.70%.
      What stocks does Bvf Partners LP Il hold?
      Bvf Partners LP Il holds: CCXI, CTIC, XENE, INFIQ, XOMA, GLYC, CNCE, SNDX, IMDZ, PIRS, FPRX, CALA, CYTK, MRUS, IDYA, PRNB, KYMR, OLMA, ELDN, CTMX, RAIN, RPTX, CGEM, THRD, GPCR, MLTX, GYRE, CASC, DVAX, NBIX, RGEN, EPRSQ, ~ARRY, AMAG, ARQL, RIGL, TBRA, CRIS, ~RPRX, LGND, PTN, ASTX, MNOV, NPSP stocks.
        What was Bvf Partners LP Il’s latest transaction?
        Bvf Partners LP Il latest transaction was an Informative Buy of $6.24M.
          What was Bvf Partners LP Il's most profitable transaction?
          Bvf Partners LP Il’s most profitable transaction was an Informative Buy of GYRE stock on July 13, 2009. The return on the trade was 622.60%.
            What is Bvf Partners LP Il's role in ChemoCentryx?
            Bvf Partners LP Il's role in ChemoCentryx is See Explanation of Responses.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.